The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindström V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M.
Al-Sawaf O, et al.
Blood. 2025 Nov 13;146(20):2406-2416. doi: 10.1182/blood.2025028899.
Blood. 2025.
PMID: 40864973